Analyst Anderson Schock from B. Riley has initiated coverage on Anika Therapeutics (ANIK, Financial) with a "Buy" recommendation and set a price target of $21. Anika Therapeutics is recognized for its three-decade expertise in hyaluronic acid production, which it utilizes in developing and marketing products aimed at managing osteoarthritis pain and advancing regenerative solutions.
The analyst highlights that Anika's osteoarthritis pain management division is particularly profitable, generating robust cash flows that support the company's ongoing advancements in regenerative solutions. The firm anticipates that the introduction of new products in Anika's regenerative segment will be pivotal in driving both growth and margin expansion for the future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Anika Therapeutics Inc (ANIK, Financial) is $23.00 with a high estimate of $28.00 and a low estimate of $20.00. The average target implies an upside of 70.75% from the current price of $13.47. More detailed estimate data can be found on the Anika Therapeutics Inc (ANIK) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Anika Therapeutics Inc's (ANIK, Financial) average brokerage recommendation is currently 1.3, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Anika Therapeutics Inc (ANIK, Financial) in one year is $22.50, suggesting a upside of 67.04% from the current price of $13.47. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Anika Therapeutics Inc (ANIK) Summary page.
